{"id":53197,"date":"2026-01-07T16:21:22","date_gmt":"2026-01-07T08:21:22","guid":{"rendered":"https:\/\/flcube.com\/?p=53197"},"modified":"2026-01-07T16:21:23","modified_gmt":"2026-01-07T08:21:23","slug":"nimbus-therapeutics-partners-with-eli-lilly-on-1-3-billion-obesity-drug-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53197","title":{"rendered":"Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal"},"content":{"rendered":"\n<p><strong>Nimbus Therapeutics<\/strong> announced a <strong>multi\u2011year research collaboration and global exclusive licensing agreement<\/strong> with <strong>Eli Lilly (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>)<\/strong> to develop a <strong>novel oral therapeutic<\/strong> for <strong>obesity and other metabolic diseases<\/strong> using Nimbus\u2019s <strong>computational chemistry and structure\u2011based drug design platform<\/strong>. The deal, valued at up to <strong>$1.3\u202fbillion<\/strong>, includes <strong>$55\u202fmillion<\/strong> in upfront and near\u2011term milestone payments plus tiered royalties on global net sales.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Nimbus Therapeutics<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Eli Lilly Inc. (NYSE: LLY)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Computational chemistry &amp; structure\u2011based drug design<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Obesity and other metabolic diseases<\/td><\/tr><tr><td><strong>Drug Type<\/strong><\/td><td>Oral small molecule (early\u2011stage discovery)<\/td><\/tr><tr><td><strong>Financial Value<\/strong><\/td><td>Up to <strong>USD\u202f1.3\u202fbillion<\/strong><\/td><\/tr><tr><td><strong>Upfront\/Near\u2011Term<\/strong><\/td><td><strong>USD\u202f55\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Milestones<\/strong><\/td><td>Development, commercialization, and sales milestones<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties on global net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-computational-chemistry-platform\">Technology Profile: Computational Chemistry Platform<\/h2>\n\n\n\n<p><strong>Nimbus\u2019s Approach<\/strong>: Leverages <strong>physics\u2011based modeling, machine learning, and structural biology<\/strong> to design <strong>highly selective small molecules<\/strong> targeting challenging metabolic pathways.<\/p>\n\n\n\n<p><strong>Key Advantages<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral Bioavailability<\/strong>: Focuses on <strong>druggable pockets<\/strong> suitable for oral administration, critical for obesity patient compliance<\/li>\n\n\n\n<li><strong>Selectivity<\/strong>: Minimizes off\u2011target effects (e.g., GI distress, cardiovascular risks) common in earlier obesity drugs<\/li>\n\n\n\n<li><strong>Speed<\/strong>: Reduces <strong>lead optimization from 24\u201136 months to 12\u201118 months<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Metabolic Target<\/strong>: Undisclosed but likely involves <strong>novel pathways beyond GLP\u20111<\/strong> (e.g., mitochondrial uncouplers, appetite circuits, energy expenditure regulators).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-obesity-amp-metabolic-diseases\">Market Opportunity: Obesity &amp; Metabolic Diseases<\/h2>\n\n\n\n<p><strong>Global Obesity Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2025<\/strong>: <strong>$30\u201135\u202fbillion<\/strong> (GLP\u20111\/GIP agents dominate)<\/li>\n\n\n\n<li><strong>2030<\/strong>: <strong>$70\u201180\u202fbillion<\/strong> (projected), driven by <strong>oral therapies<\/strong> and <strong>combination regimens<\/strong><\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: <strong>40\u201150%<\/strong> of patients discontinue injectables due to <strong>side effects<\/strong>; <strong>oral small molecules<\/strong> could capture <strong>30%<\/strong> of this segment<\/li>\n<\/ul>\n\n\n\n<p><strong>Lilly\u2019s Obesity Franchise<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Zepbound<\/strong> (tirzepatide): <strong>$5\u202fbillion<\/strong> in 2025 sales, but injectable only<\/li>\n\n\n\n<li><strong>Orforglipron<\/strong> (oral GLP\u20111): Phase\u202fIII, but <strong>efficacy lag<\/strong> vs. injectables<\/li>\n\n\n\n<li><strong>Nimbus Partnership<\/strong>: Targets <strong>next\u2011generation oral therapy<\/strong> with <strong>potential blockbuster<\/strong> status<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug\/Platform<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Route<\/th><\/tr><\/thead><tbody><tr><td><strong>Zepbound<\/strong><\/td><td>Eli Lilly<\/td><td>GLP\u20111\/GIP<\/td><td>Marketed<\/td><td>Injectable<\/td><\/tr><tr><td><strong>Orforglipron<\/strong><\/td><td>Eli Lilly<\/td><td>Oral GLP\u20111<\/td><td>Phase\u202fIII<\/td><td>Oral<\/td><\/tr><tr><td><strong>Wegovy<\/strong><\/td><td>Novo Nordisk<\/td><td>GLP\u20111<\/td><td>Marketed<\/td><td>Injectable<\/td><\/tr><tr><td><strong>Danuglipron<\/strong><\/td><td>Pfizer<\/td><td>Oral GLP\u20111<\/td><td>Phase\u202fIII (paused)<\/td><td>Oral<\/td><\/tr><tr><td><strong>Nimbus Platform<\/strong><\/td><td><strong>Nimbus + Lilly<\/strong><\/td><td>Novel oral target<\/td><td><strong>Discovery<\/strong><\/td><td><strong>Oral<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Gap<\/strong>: Nimbus\u2019s <strong>novel oral mechanism<\/strong> could <strong>differentiate from crowded GLP\u20111 space<\/strong> and <strong>complement Lilly\u2019s portfolio<\/strong> for combination therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms-amp-milestone-structure\">Financial Terms &amp; Milestone Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount<\/th><th>Trigger<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront<\/strong><\/td><td>$30\u201140\u202fmillion<\/td><td>Agreement signing<\/td><\/tr><tr><td><strong>Near\u2011Term Milestones<\/strong><\/td><td>$15\u201125\u202fmillion<\/td><td>Lead candidate nomination, IND\u2011enabling studies<\/td><\/tr><tr><td><strong>Development Milestones<\/strong><\/td><td>~$600\u202fmillion<\/td><td>Phase\u202fI\u2011III completions<\/td><\/tr><tr><td><strong>Commercial Milestones<\/strong><\/td><td>~$700\u202fmillion<\/td><td>Regulatory approvals, sales thresholds<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>$1.3\u202fbillion<\/strong><\/td><td>Excluding royalties<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Low\u2011mid double\u2011digit %<\/td><td>Tiered on global net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Risk Sharing<\/strong>: Lilly\u2019s participation in <strong>early R&amp;D costs<\/strong> signals <strong>high confidence<\/strong> in Nimbus\u2019s platform, while Nimbus retains <strong>upside<\/strong> without bearing late\u2011stage clinical risk.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>For Nimbus<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Efficiency<\/strong>: <strong>$55\u202fmillion<\/strong> funds <strong>2\u20113 years of discovery<\/strong> without dilution<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Lilly partnership <strong>de\u2011risks technology<\/strong> and attracts future collaborators<\/li>\n\n\n\n<li><strong>Royalty Stream<\/strong>: Potential <strong>$200\u2011300\u202fmillion<\/strong> annually at peak sales if drug reaches market<\/li>\n<\/ul>\n\n\n\n<p><strong>For Lilly<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Gap Fill<\/strong>: Addresses <strong>oral obesity drug shortage<\/strong> and <strong>next\u2011generation targets<\/strong> beyond GLP\u20111<\/li>\n\n\n\n<li><strong>Cost Savings<\/strong>: In\u2011licensing at <strong>discovery stage<\/strong> reduces per\u2011asset cost vs. <strong>$1\u20112\u202fbillion<\/strong> internal discovery spend<\/li>\n\n\n\n<li><strong>Speed to Market<\/strong>: Nimbus\u2019s platform could <strong>shorten discovery by 12\u201118 months<\/strong>, capturing <strong>first\u2011mover advantage<\/strong> in emerging oral obesity class<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-pathway\">Development Pathway<\/h2>\n\n\n\n<p><strong>Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lead Candidate Selection<\/strong>: <strong>Q4\u202f2026<\/strong> (12\u2011month discovery sprint)<\/li>\n\n\n\n<li><strong>IND Filing<\/strong>: <strong>Q2\u202f2028<\/strong> (18\u2011month optimization)<\/li>\n\n\n\n<li><strong>Phase\u202f1 Initiation<\/strong>: <strong>Q3\u202f2028<\/strong> (Lilly\u2011led)<\/li>\n\n\n\n<li><strong>Commercial Launch<\/strong>: <strong>2032\u20112033<\/strong> (if successful)<\/li>\n<\/ul>\n\n\n\n<p><strong>Efficacy Bar<\/strong>: Must demonstrate <strong>\u226510\u201112% body weight reduction<\/strong> (non\u2011inferior to oral GLP\u20111s) with <strong>superior tolerability<\/strong> to justify <strong>premium pricing<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Nimbus\u2019s discovery timeline, milestone achievements, and competitive positioning in the obesity market. Actual results may differ materially due to clinical trial outcomes, competitive responses, and regulatory acceptance of novel mechanisms.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nimbus Therapeutics announced a multi\u2011year research collaboration and global exclusive licensing agreement with Eli Lilly&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53200,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[199,4532,911,86],"class_list":["post-53197","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-eli-lilly","tag-nimbus-therapeutics","tag-nyse-lly","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nimbus Therapeutics announced a multi\u2011year research collaboration and global exclusive licensing agreement with Eli Lilly (NYSE: LLY) to develop a novel oral therapeutic for obesity and other metabolic diseases using Nimbus\u2019s computational chemistry and structure\u2011based drug design platform. The deal, valued at up to $1.3\u202fbillion, includes $55\u202fmillion in upfront and near\u2011term milestone payments plus tiered royalties on global net sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53197\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal\" \/>\n<meta property=\"og:description\" content=\"Nimbus Therapeutics announced a multi\u2011year research collaboration and global exclusive licensing agreement with Eli Lilly (NYSE: LLY) to develop a novel oral therapeutic for obesity and other metabolic diseases using Nimbus\u2019s computational chemistry and structure\u2011based drug design platform. The deal, valued at up to $1.3\u202fbillion, includes $55\u202fmillion in upfront and near\u2011term milestone payments plus tiered royalties on global net sales.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53197\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T08:21:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T08:21:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0701.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53197#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53197\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal\",\"datePublished\":\"2026-01-07T08:21:22+00:00\",\"dateModified\":\"2026-01-07T08:21:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53197\"},\"wordCount\":619,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53197#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0701.webp\",\"keywords\":[\"Eli Lilly\",\"Nimbus Therapeutics\",\"NYSE: LLY\",\"Obesity\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53197#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53197\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53197\",\"name\":\"Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53197#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53197#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0701.webp\",\"datePublished\":\"2026-01-07T08:21:22+00:00\",\"dateModified\":\"2026-01-07T08:21:23+00:00\",\"description\":\"Nimbus Therapeutics announced a multi\u2011year research collaboration and global exclusive licensing agreement with Eli Lilly (NYSE: LLY) to develop a novel oral therapeutic for obesity and other metabolic diseases using Nimbus\u2019s computational chemistry and structure\u2011based drug design platform. The deal, valued at up to $1.3\u202fbillion, includes $55\u202fmillion in upfront and near\u2011term milestone payments plus tiered royalties on global net sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53197#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53197\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53197#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0701.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0701.webp\",\"width\":1080,\"height\":608,\"caption\":\"Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53197#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Nimbus Therapeutics announced a multi\u2011year research collaboration and global exclusive licensing agreement with Eli Lilly (NYSE: LLY) to develop a novel oral therapeutic for obesity and other metabolic diseases using Nimbus\u2019s computational chemistry and structure\u2011based drug design platform. The deal, valued at up to $1.3\u202fbillion, includes $55\u202fmillion in upfront and near\u2011term milestone payments plus tiered royalties on global net sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53197","og_locale":"en_US","og_type":"article","og_title":"Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal","og_description":"Nimbus Therapeutics announced a multi\u2011year research collaboration and global exclusive licensing agreement with Eli Lilly (NYSE: LLY) to develop a novel oral therapeutic for obesity and other metabolic diseases using Nimbus\u2019s computational chemistry and structure\u2011based drug design platform. The deal, valued at up to $1.3\u202fbillion, includes $55\u202fmillion in upfront and near\u2011term milestone payments plus tiered royalties on global net sales.","og_url":"https:\/\/flcube.com\/?p=53197","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-07T08:21:22+00:00","article_modified_time":"2026-01-07T08:21:23+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0701.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53197#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53197"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal","datePublished":"2026-01-07T08:21:22+00:00","dateModified":"2026-01-07T08:21:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53197"},"wordCount":619,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53197#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0701.webp","keywords":["Eli Lilly","Nimbus Therapeutics","NYSE: LLY","Obesity"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53197#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53197","url":"https:\/\/flcube.com\/?p=53197","name":"Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53197#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53197#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0701.webp","datePublished":"2026-01-07T08:21:22+00:00","dateModified":"2026-01-07T08:21:23+00:00","description":"Nimbus Therapeutics announced a multi\u2011year research collaboration and global exclusive licensing agreement with Eli Lilly (NYSE: LLY) to develop a novel oral therapeutic for obesity and other metabolic diseases using Nimbus\u2019s computational chemistry and structure\u2011based drug design platform. The deal, valued at up to $1.3\u202fbillion, includes $55\u202fmillion in upfront and near\u2011term milestone payments plus tiered royalties on global net sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53197#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53197"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53197#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0701.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0701.webp","width":1080,"height":608,"caption":"Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53197#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0701.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53197"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53197\/revisions"}],"predecessor-version":[{"id":53201,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53197\/revisions\/53201"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53200"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}